Universally usable process for reducing the chlorine content of organotetraphosphites.

The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the .sub.4.sub.1 integrin on mesenchymal stem cells and for the surface of bone.

The present invention features compounds effective in inhibiting active against Hepatitis C virus (HCV) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

An electrolyte solution capable of providing electrochemical devices whose internal resistance is less likely to increase even after repeated charge and discharge and whose cycle capacity retention ratio is high. The electrolyte solution contains a solvent, an electrolyte salt, and a phosphate in an amount of 0.001 to 15 mass % relative to the solvent and represented by the formula (1): (R.sup.11O)(R.sup.12O)PO.sub.2M, where R.sup.11, R.sup.12 and M are as defined herein.

Universally usable process for reducing the chlorine content of organotetraphosphites.

The instant disclosure relates to phosphorus-containing compounds that can be used to form flame retardant phosphorus-containing resins, and also can serve as a hardener for a flame retardant epoxy resin compositions. In particular, the phosphorus-containing compounds are modified with acyloxy groups (O(CO)R), as shown below. Incorporation of the acyloxy groups results in resins that are water resistant and exhibit improved dielectric properties. ##STR00001##

The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

A lubricant composition comprising (a) an oil of lubricating viscosity; (b) at least two nitrogen-containing materials, comprising (i) at least one amide of the formula R.sup.3C(O)NR.sup.1R.sup.2 and (ii) at least one tertiary amine being represented by the formula R.sup.4R.sup.5NR.sup.6 where R.sup.4 and R.sup.5 are alkyl groups of at least 6 carbon atoms and R.sup.6 is a polyhydroxyl-containing alkyl group or a polyhydroxyl-containing alkoxyalkyl group; (c) a functionalized dispersant component, and (d) at least one diallyl phosphite, provides good lubricant performance for a continuously variable transmission.

A method for regenerating deactivated acidic ionic liquid is described. The method involves reducing a level of free hydrochloric acid in the deactivated acidic ionic liquid in a removal zone using at least one of heat, a stripping fluid, reduced pressure, and liquid-liquid extraction to form a deactivated acidic ionic liquid having a reduced level of free hydrochloric acid; and regenerating the deactivated acidic ionic liquid having the reduced level of free hydrochloric acid.